The purpose of this study is to verify whether the reduction of cyclosporine dosages associated with Everolimus administration may improve renal function as compared to patients maintained on standard immunosuppressive therapy
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
200
cyclosporine dose reduced of 50% after introduction of everolimus
Heart Transplant Center Ospedali Riuniti
Bergamo, Italy
Heart Transplantad Center OspedaliRiuniti Bergamo
Bergamo, Italy
Renal function Evaluated measuring Creatinine, Creatinine Clearance (MDRD and Cockcroft-Gault) and Urinary excretion of Protein, albumin and alpha-1-microglobulin
Time frame: 2 years
All cause mortality, infections, incidence of acute myocardial rejection, Heart Failure, Chronic Rejection, Mace
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.